SGLT2 inhibition in people with Heart Failure – what does the evidence tell us?
16 Nov 2022
Heart and Kidney Clinic
It is over a decade since the initial CVOT trials signaled the potential benefit of the SGLT2inhibitors in heart failure since when focused research has provided evidence to support the utility of SGLT2 inhibition across the heart failure spectrum. In this session, I plan to share that evidence and look at how SGLT2 inhibitors are currently used in the management of heart failure and based on the evidence how this is changing
- To be aware of the trial evidence underpinning the use of SGLT2i in heart failure
- To be aware of the current guidance around the use of SGLT2i in heart failure
- To be aware of how SGLT2 inhibitors are currently used in the modern treatment of heart failure and how this is changing.